explore -WSS

explore

author：comprehensive 2025-08-26 03:42:28 - browse：54

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

WSS

After sickle

The woman behind the Dana Farber

Roche to buy Carmot Therapeutics, developer of obesity drugs

CMS should re

Pharmacists can make shortage drugs, but at what cost?

The EU Joint Clinical Assessment needs to live up to its promise

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Researchers explore possible ties between long Covid, menopause

Tori Bowie and the unacceptable rates of Black maternal death

Congenital heart disease patients face new threat of heart failure

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why sickle cell disease is getting the first CRISPR treatment

Drug repurposing or repositioning? The language matters

Will Ozempic

Hollywood unions extend contract negotiations for actors

Beam Therapeutics to lay off 20% of its staff, re

knowledge

Senate committee scrutinizes Medicare Advantage brokers

In diabetes hearing, Sanders takes on a new foe: food makers

STAT Summit: GSK CEO on pharma giant's new direction

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

The woman behind the Dana Farber

STAT Summit: Michael J. Fox on progress in Parkinson's research

knowledge

focus

hotspot

entertainment